AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04953897
Drug: ASTX727
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-dose oral administration of once-daily decitabine (35 mg) and cedazuridine (100 mg)
Trial: NCT06255912
Drug: LTC004 + MIL-97
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose group 1：MIL97:0.2mg/kg,Day1,Q3W,LTC004:90ug/kg,Day3,Q3W Dose group 2:MIL97:0.2mg/kg,Day1,Q3W,LTC004:180ug/kg,Day3,Q3W Dose group -1:MIL97:0.2mg/kg,Day1,Q3W,LTC004:45ug/kg,Day3,Q3W
Trial: NCT06137144
Drug: AZD3470
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD3470 is a novel, potent and selective, second-generation, Methylthioadenosine (MTA)-selective, small molecule inhibitor of PRMT5.
Trial: NCT05705336
Drug: Placebo pills
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 3 standard placebo pills administered orally 2 hours before the surgical incision.
Trial: NCT04833426
Drug: Testosterone gel
RxNorm normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical gel containing testosterone
Trial: NCT04833426
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical gel without active substance
Trial: NCT05896371
Drug: 177Lu-PSMA-I&T - escalating renal absorbed dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized 177Lu-PSMA-I\&T injected activity
Trial: NCT05896371
Drug: 177Lu-PSMA-I&T - recommended phase 2 regime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized 177Lu-PSMA-I\&T injected activity
Trial: NCT05372653
Drug: OPA-15406
RxNorm normalized name: O-PHTHALALDEHYDE 22 g in 4000 mL TOPICAL LIQUID [Safe OPA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% or 1% ointment, topical, twice daily, for 52 weeks
Trial: NCT06393374
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000 mg/m\^2 to 1250 mg/m\^2 by mouth BID
Trial: NCT04985812
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo to JNJ-67484703.
Trial: NCT05646381
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT04951609
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo orally.
Trial: NCT04619420
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to JNJ-63733657 will be administered by IV infusion.
Trial: NCT04550104
Drug: AZD1390
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT04550104
Drug: AZD5305
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT06479226
Drug: cetylpyridinium chloride (0.075%) and zinc alcohol free mouthwash
RxNorm normalized name: cetylpyridinium chloride / zinc chloride Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mouthrinse
Trial: NCT05039515
Drug: IPN60130
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release capsule containing high dose of the drug substance.
Trial: NCT05039515
Drug: IPN60130
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release capsule containing low dose of the drug substance.
Trial: NCT05039515
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be supplied as powder filled hard capsules
Trial: NCT05591118
Drug: Anticoagulant Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will receive anticoagulation for a minimum of 3 months.
Trial: NCT05661851
Drug: Investigational Lubricating Eye Drop in a Novelia® bottle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational Product
Trial: NCT05661851
Drug: Blink® Tears eye Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Product
Trial: NCT05841758
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo during a 12 months double blind placebo-controlled period
Trial: NCT05835479
Drug: Co-Trimoxazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral co-trimoxazole or Intravenous (IV) co-trimoxazole for infusion. Anti fungal medication
Trial: NCT04232657
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thirteen (13) of the thirty-nine (39) subjects enrolled in this study will be randomly selected to receive placebo (NS SQ) injections for 12 months (baseline - month 11). The placebo injections will be administered by an unblinded healthcare professional (registered nurse / physician). Participants will be blinded to their group assignment (romosozumab treatment or placebo).
Trial: NCT05773950
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On the day of surgery, in the preoperative holding area, the principal investigator administers the study drug to the participants. During the study drug administration period, the principal investigator observes the presence of specific symptoms and abnormalities at the injection site of participants.~In the case of the control group, the study drug is 150 ml of normal saline, which is visually indistinguishable from the dilute solution of the fosaprepitant, administered over 30 minutes.
Trial: NCT05055050
Drug: UGN-201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical 200 mg /50 ml x 1 dose
Trial: NCT04717713
Drug: steroid injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: steroid injection at surgical location
Trial: NCT04717713
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline injection at surgical location
Trial: NCT04958031
Drug: CVL-871 3.0 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVL-871 3.0 mg QD oral (tablet), once per day for 12 weeks (stepped up-titration of dose days 1-21)
Trial: NCT04958031
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo QD, oral (tablet), once per day for 12 weeks
Trial: NCT05500898
Drug: DWP16001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, multiple doses of DWP16001
Trial: NCT04772313
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive MTX during the run-in period then pegloticase with MTX for up to 24 weeks during the treatment period. Participants may opt to receive pegloticase with MTX for an additional 24 weeks.
Trial: NCT05245084
Drug: D013, D326, D337
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD, PO
Trial: NCT05925114
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as an oral capsule that looks identical to S-309309 capsule
Trial: NCT04853329
Drug: CPO107
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD20-CD47 Bispecific Fusion Protein
Trial: NCT05625568
Drug: VYNT-0126
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid for oral administration once daily
Trial: NCT06784999
Drug: sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. Intravenous sufentanil starting at a dose of 0.5 mcg/kg/min hr ideal body weight (IBW) at the beginning of the case, prior to surgical incision, with a discontinuation of the infusion when the surgical microscope is removed from the patient field and the closure of the incision(s) begins. (n=64)
Trial: NCT05121246
Drug: MB05 (Proposed palivizumab biosimilar)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IM dose of 3 mg/kg
Trial: NCT05121246
Drug: EU-Synagis®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IM dose of 3 mg/kg
Trial: NCT05121246
Drug: US-Synagis®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IM dose of 3 mg/kg
Trial: NCT04711824
Drug: Physicians Choice systemic chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib: 300mg PO BID; Days 1-21 Paclitaxel: 80 mg/m2 IV over 60 min; Day 1 and 8 Nab-paclitaxel:100 mg/m2 IV over 30 min; Day 1 and 8 Eribulin: 1.4 mg/m2 IV over 2-5 min; Day 1 and 8 Carboplatin: AUC 2 mg/ml/min IV over 30-60 min; Day 1 and 8 Cisplatin: 75 mg/m2 IV over 30-60 min; Day 1 Capecitabine: 1000 mg/m2 PO BID; Days 1-14 Gemcitabine: 1000 mg/m2 IV over 30 min; Day 1 and 8 Gemcitabine + Carboplatin: 1000mg/m2 IV over 30-60 min; Day 1 and 8
Trial: NCT05784129
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered subcutaneously.
Trial: NCT04711109
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given SC
Trial: NCT05676034
Drug: AMX0035
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMX0035
Trial: NCT04829318
Drug: SSRI/SNRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will continue to take SSRI/SNRI that is approved for use in depression in their country of participation; off-label use of any SSRI/SNRI is not permitted. The continuing SSRI/SNRI dosage may be optimized throughout the study, at the investigator's discretion and based on the summary of product characteristics (SmPC) (or local equivalent, if applicable). During this LTE study, investigators will be allowed to switch individual participant's SSRI/SNRI for tolerability issues.
Trial: NCT05626023
Drug: Human TH-SC01 cell injection
RxNorm normalized name: HUMAN BREAST TUMOR CELL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection of human TH-SC01 cell injection
Trial: NCT04677530
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered orally.
Trial: NCT05057806
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will be administered orally once per day for 3 months
Trial: NCT03643367
Drug: Control Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Included patients randomized in control group, intravenouse sedation is continued with propofol
Trial: NCT04936308
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo as SC injection.
Trial: NCT05041842
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole (1 mg/day) or letrozole (2.5 mg/day) or fulvestrant (2x250 mg at day 1 and day 15 then every 4 weeks after the first injection)
Trial: NCT04547166
Drug: HLX04、
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5mg/kg, IV, every 3 weeks (D1 of each cycle), non-reducible.
Trial: NCT05268003
Drug: Mini-hyper CVD
RxNorm normalized name: Hyper-Sal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by IV (vein)
Trial: NCT05169814
Drug: Micro/nanobubble (MNB) - Irrigation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An MNB solution will be used as an irrigation solution to improve wound oxygenation in ischemic tissue (e.g. ischemic surgical tissue, traumatic wounds, and failing replants). The MNB solution will be used in wet-to-dry wound care dressings with daily scheduled dressing changes.
Trial: NCT05169814
Drug: Micro/nanobubble (MNB) - Negative Pressure Wound Therapy with Instillation (NPWTi)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPWTi with MNB will be applied to the wound with 20-minute instillation periods every 3 hours (standard instillation settings) with dressing changes every 3-5 days.
Trial: NCT04827901
Drug: XEN1101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two 10 mg capsules
Trial: NCT04827901
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT05713799
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06434233
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive Acetaminophen 500 mg orally every 6 hours scheduled x 30 tablets at post-operative discharge.~All patients will be instructed to take Acetaminophen around the clock for the first 72 hours and as needed thereafter.
Trial: NCT06434233
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All patients will receive Ibuprofen 600 mg orally every 6 hours scheduled x 30 tablets at post-operative discharge.~All patients will be instructed to take Ibuprofen around the clock for the first 72 hours and as needed thereafter.
Trial: NCT02446379
Drug: The marketed product 2-5 MBq/kg 18F-fluorodeoxyglucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The FDG is injected at least 120 minutes prior to the imaging by the EnLightTM and LightPathTM Imaging Systems
Trial: NCT06136507
Drug: FRSW107
FDA approved: no
EMA approved: no
PMDA approved: no
Description: experimental：Q3D.≥50EDs， Expansion phase：Q3D.100EDs
Trial: NCT05514548
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Matching size and number of tablets
Trial: NCT06028438
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered intravenously.
Trial: NCT04269993
Drug: Cannabis: placebo and medium THC/medium CBD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaporized cannabis was administered to participants (placebo and medium THC/medium CBD).
Trial: NCT05094336
Drug: Comparator AMG 193 Test Tablet
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator AMG 193 test tablet: Orally via tablet. Only participants in the DSPS group of the Part 1a, Phase 1: AMG 193 Monotherapy Dose Exploration, and Part 1j, Phase 1 arms will receive comparator AMG 193 test tablet.
Trial: NCT05867121
Drug: RO7496353
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7496353 will be administered as per the schedules specified in the respective arms.
Trial: NCT05867121
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine will be administered as per the schedules specified in the respective arms
Trial: NCT05564377
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05564377
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00626613
Drug: Risperdal,reminyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperdal:The dosage of treatment medication will begin with 0.5 ml/ per day (0.5mg), The maximum dose will be 2ml/ per day reminyl:8 mg/ per day
Trial: NCT06312137
Drug: Rescue medication
RxNorm normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants are allowed to take rescue medication to prevent hypersensitivity and/or infusion reactions as a premedication to study treatment. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are antihistamine, H2 receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent. A steroid mouthwash (dexamethasone or equivalent) may be given as prophylaxis for stomatitis/oral mucositis.
Trial: NCT05474729
Drug: minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: minocycline capsule 100mg per day orally
Trial: NCT05363605
Drug: [225Ac]-FPI-1966
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[225Ac\]-FPI-1966 is a targeted alpha therapeutic that consists of vofatamab, a bifunctional chelate, and actinium-225, an alpha particle emitting radionuclide. In Phase 1, the dose depends on cohort assignment. In Phase 2, the RP2D regimen will be administered.
Trial: NCT04885634
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of volume-matched placebo once weekly
Trial: NCT05045469
Drug: dian dao san
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dian dao san and placebo will be used in the rosacea lesions twice a day for 6 weeks
Trial: NCT04988555
Drug: Enzomenib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DSP-5336 orally
Trial: NCT06485648
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control: G(glucocorticoid) + i.v. Normal saline
Trial: NCT05549947
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group D：placebo
Trial: NCT06148402
Drug: Fruquintinib plus camrelizumab and capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fruquintinib 5 mg once daily, 2 weeks on/1 week off, plus camrelizumab 200 mg Q3W and capecitabine 750mg/square meter twice, 2 weeks on/1 week off, q3w
Trial: NCT06077669
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral placebo
Trial: NCT05891834
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet, once daily, oral
Trial: NCT05683886
Drug: KC1036
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients take 60mg QD of KC1036 for the efficacy and safety study. KC1036 are given orally once daily, 21 days as a cycle.
Trial: NCT05370547
Drug: Fludarabine and cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients should be received FC regimen conditioning 3 to 5 days prior to CAR-T cell infusion. The recommended regimen is intravenous fludarabine (25-30 mg/m\^2) and cyclophosphamide (250-500 mg/m\^2) daily for 3 consecutive days. The clinician may also adjust the cleansing regimen according to the patient's actual situation.
Trial: NCT04882072
Drug: Glucorticoid Taper Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticoid will be administered orally.
Trial: NCT05632809
Drug: NKTR-255
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by IV (vein)
Trial: NCT04750577
Drug: Placebo matching BI 685509
FDA approved: no
EMA approved: no
PMDA approved: no
Description: film-coated tablet
Trial: NCT05957302
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mcg of fentanyl diluted in 10 mL saline (10 mcg /mL) and patient will receive 0.1 mL/kg
Trial: NCT04935762
Drug: CST-103, CST-107, matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CST-103 and matching placebo orange capsules; CST-107 and matching placebo white capsules
Trial: NCT06340360
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Injection solution Route of administration: subcutaneous
Trial: NCT05213624
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching BI 764198
Trial: NCT06058013
Drug: NMRA-335140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive NMRA-335140 at a dose of 80 mg QD, orally
Trial: NCT06058013
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered orally
Trial: NCT06309485
Drug: WGI-0301 at MTD/RP2D dose IV infusion, QW
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WGI-0301 is a lipid nanoparticle preparation of Archexin®, a 20-mer oligonucleotide that is complementary to Akt-1 mRNA, formulated for the treatment of advanced HCC.
Trial: NCT06309485
Drug: WGI-0301 at MTD/RP2D -1 dose IV infusion, QW
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WGI-0301 is a lipid nanoparticle preparation of Archexin®, a 20-mer oligonucleotide that is complementary to Akt-1 mRNA, formulated for the treatment of advanced HCC.
Trial: NCT05701774
Drug: DCCR
RxNorm normalized name: Diazoxide Choline Controlled-Release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily oral administration
Trial: NCT05717062
Drug: Placebo intravenous form
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intravenous placebo will be saline (0.9%). Blinding will be ensured by covering the bag containing the investigational product with opaque covers.
Trial: NCT05717062
Drug: Placebo - oral form
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo is supplied as a white film-coated oval tablet to match the appearance of the LY333013 250 mg tablet and contains a subset of the excipients present in the active tablet formulation: lactose monohydrate, microcrystalline cellulose, and magnesium stearate
Trial: NCT06209047
Drug: bronchoscopic airway clearance followed by local instillation of gentamicin and dexamethasone
RxNorm normalized name: Betagen brand of Betamethasone and Gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bronchoscopic airway clearance followed by local instillation of gentamicin and dexamethasone
Trial: NCT06562192
Drug: [177Lu]Lu-NNS309
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioligand therapy
Trial: NCT05288777
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dosed at 825 mg/m2 +/- 150mg twice per day for a total duration of 6 months
Trial: NCT06481891
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as a tablet(s) (identical to the sotagliflozin tablet in appearance), orally once daily.
Trial: NCT06502964
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive placebo patches
Trial: NCT05307692
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered orally as a tablet.
Trial: NCT05421858
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for caspofungin (IV infusion)